Tekmira's pipeline currently consists of its lead RNAi therapeutic product candidate ApoB SNALP, which is being developed as a treatment for high LDL, or "bad" cholesterol.
This agreement provides BMS with the opportunity to validate the function of certain cellular targets by using SNALP formulations supplied by Tekmira.
"We believe this work justifies the immediate development of Ebola SNALP
as a countermeasure to treat Ebola infected patients, either in outbreaks or accidental laboratory exposures," he said.
We continue to collaborate with pharmaceutical and biotechnology companies thereby broadening the use of our leading SNALP
This agreement is consistent with our strategy of working with leading pharmaceutical companies to help them advance products based on our SNALP
technology, and to leverage this work in order to advance our own products."
In parallel, nanoplexes such as chitosan/PLGA (Poly(D,L-lactide-co-glycolide)) and SNALPs
(stable nucleic acid lipid particles) have been used for the delivery of miR-34a mimics to treat multiple myeloma xenografts in SCID mice [45, 46].